AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis
Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.
2 sourcesBiologic therapies
00